Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heidel

Showing results (621-630 of 715) with videos related to

Pageof 72
Sort By:
Hemasphere|March 18, 2025
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistryHyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, et al.
Cancer Medicine|January 26, 2025
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG StudyJonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, et al.
Haematologica|March 18, 2014
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and functionDenise Wolleschak, Thomas S Mack, Florian Perner, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Cell Stem Cell|December 7, 2014
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapyClaudia Bruedigam, Frederik O Bagger, Florian H Heidel, et al.
Oncology Research|May 1, 2026
Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort StudyLaura Duzzi, Nora Möhn, Emily Narten, et al.
Leukemia|January 18, 2020
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Surgery|July 21, 2022
Prehospital plasma is associated with survival principally in patients transferred from the scene of injury: A secondary analysis of the PAMPer trialRachel E Lewis, Sruthi L Muluk, Katherine M Reitz, et al.
Leukemia|October 3, 2019
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Npj Drug Discovery|July 1, 2026
The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivityJ S Wall, A D Williams, M Balachandran, et al.
Pageof 72

Showing results (621-630 of 715) with videos related to

Sort By:
Pageof 72
Hemasphere|March 18, 2025
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistryHyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, et al.
Cancer Medicine|January 26, 2025
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG StudyJonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, et al.
Haematologica|March 18, 2014
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and functionDenise Wolleschak, Thomas S Mack, Florian Perner, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Cell Stem Cell|December 7, 2014
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapyClaudia Bruedigam, Frederik O Bagger, Florian H Heidel, et al.
Oncology Research|May 1, 2026
Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort StudyLaura Duzzi, Nora Möhn, Emily Narten, et al.
Leukemia|January 18, 2020
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Surgery|July 21, 2022
Prehospital plasma is associated with survival principally in patients transferred from the scene of injury: A secondary analysis of the PAMPer trialRachel E Lewis, Sruthi L Muluk, Katherine M Reitz, et al.
Leukemia|October 3, 2019
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Npj Drug Discovery|July 1, 2026
The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivityJ S Wall, A D Williams, M Balachandran, et al.
Pageof 72